ES2982022T3 - Formulaciones tópicas de detomidina - Google Patents

Formulaciones tópicas de detomidina Download PDF

Info

Publication number
ES2982022T3
ES2982022T3 ES18701853T ES18701853T ES2982022T3 ES 2982022 T3 ES2982022 T3 ES 2982022T3 ES 18701853 T ES18701853 T ES 18701853T ES 18701853 T ES18701853 T ES 18701853T ES 2982022 T3 ES2982022 T3 ES 2982022T3
Authority
ES
Spain
Prior art keywords
detomidine
formulation
salt
topical
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18701853T
Other languages
English (en)
Spanish (es)
Inventor
Omer Tsipori
Mark Zamansky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clexio Bioscience Ltd
Original Assignee
Clexio Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clexio Bioscience Ltd filed Critical Clexio Bioscience Ltd
Application granted granted Critical
Publication of ES2982022T3 publication Critical patent/ES2982022T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18701853T 2017-01-06 2018-01-05 Formulaciones tópicas de detomidina Active ES2982022T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762443174P 2017-01-06 2017-01-06
PCT/US2018/012579 WO2018129313A1 (en) 2017-01-06 2018-01-05 Topical detomidine formulations

Publications (1)

Publication Number Publication Date
ES2982022T3 true ES2982022T3 (es) 2024-10-14

Family

ID=61054537

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18701853T Active ES2982022T3 (es) 2017-01-06 2018-01-05 Formulaciones tópicas de detomidina

Country Status (15)

Country Link
US (2) US20190343805A1 (enExample)
EP (1) EP3565526B1 (enExample)
JP (1) JP2020505322A (enExample)
KR (1) KR20190110561A (enExample)
CN (1) CN110114059A (enExample)
AU (1) AU2018205217B2 (enExample)
BR (1) BR112019011961A2 (enExample)
CA (1) CA3049389A1 (enExample)
DK (1) DK3565526T3 (enExample)
ES (1) ES2982022T3 (enExample)
HU (1) HUE068070T2 (enExample)
IL (1) IL266448B2 (enExample)
MX (1) MX382949B (enExample)
PL (1) PL3565526T3 (enExample)
WO (1) WO2018129313A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210137830A1 (en) * 2018-07-11 2021-05-13 Clexio Biosciences Ltd. Topical detomidine formulations
WO2020016827A1 (en) * 2018-07-18 2020-01-23 Clexio Biosciences Ltd. Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
KR20220002950A (ko) * 2019-05-01 2022-01-07 클렉시오 바이오사이언시스 리미티드 소양증의 치료 방법
WO2020222192A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
FR3169318A1 (fr) 2024-12-11 2026-06-12 Tarian Pharma Composition comprenant un vasoconstricteur pour prevenir et/ou traiter des neuropathies peripheriques et/ou douleurs neuropathiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10256774A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
EP2558101A4 (en) * 2010-04-15 2013-09-18 Univ Mcgill TOPICAL TREATMENTS OF PAIN
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
EP2803668A1 (en) * 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
JP6621747B2 (ja) * 2013-08-14 2019-12-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Also Published As

Publication number Publication date
JP2020505322A (ja) 2020-02-20
IL266448B2 (en) 2023-11-01
EP3565526B1 (en) 2024-04-17
CA3049389A1 (en) 2018-07-12
HUE068070T2 (hu) 2024-12-28
US20230172909A1 (en) 2023-06-08
WO2018129313A1 (en) 2018-07-12
MX382949B (es) 2025-03-13
EP3565526A1 (en) 2019-11-13
PL3565526T3 (pl) 2024-09-09
BR112019011961A2 (pt) 2019-11-05
KR20190110561A (ko) 2019-09-30
IL266448B1 (en) 2023-07-01
AU2018205217B2 (en) 2023-11-09
IL266448A (en) 2019-06-30
MX2019008115A (es) 2019-10-24
CN110114059A (zh) 2019-08-09
AU2018205217A1 (en) 2019-05-23
US20190343805A1 (en) 2019-11-14
DK3565526T3 (en) 2024-05-13

Similar Documents

Publication Publication Date Title
US20230172909A1 (en) Topical detomidine formulations
ES2445443T3 (es) Solución tópica no acuosa de diclofenaco y proceso para la preparación de la misma
CA2466536C (en) Transdermal transport of compounds
US20180296506A1 (en) High concentration local anesthetic formulations
US20060140986A1 (en) Anesthetic composition for topical administration
US20210267998A1 (en) Methods and compositions for treatment of peripheral neuropathies
ES2585253T3 (es) Composiciones para prevenir la pérdida de cabello o para estimular el crecimiento del cabello
US20040131665A1 (en) Topical anesthetic formulation
Macedo et al. Microneedles enhance topical delivery of 15-deoxy-Δ12, 14-prostaglandin J2 and reduce nociception in temporomandibular joint of rats
JP7534795B2 (ja) そう痒症を治療する方法
BRPI0609929A2 (pt) método transdérmico e esparadrapo para náusea
CN110402142A (zh) 含局麻药的酸性乳液组合物
EA007351B1 (ru) Фармацевтическая композиция для чрескожной доставки физиологически активных агентов
US20110218218A1 (en) Formulations Of Indanylamines And The Use Thereof As Local Anesthetics And As Medication For Chronic Pain
US20220305076A1 (en) Topical cyclosporine for treating psoriasis and other ailments
US12576049B1 (en) Onychomycosis treatment methods
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法
BR112021003746A2 (pt) sistema de distribuição transdermal de fármacos
Thacker et al. EFFECT OF ADDING FENTANYL TO LOCAL ANAESTHETICS IN BRACHIAL PLEXUS BLOCK ON THE ONSET AND DURATION OF ANESTHESIA AND POSTOPERATIVE ANALGESIA